Related trials

ENGAGE-AF TIMI 48 High dose, 2013 - edoxaban vs warfarin standard dose

AVERROES, 2011 - apixaban vs aspirin

ARISTOTLE, 2011 - apixaban vs warfarin standard dose

ROCKET-AF, 2010 - rivaroxaban vs warfarin standard dose

ACTIVE A, 2009 - aspirin + clopidogrel vs aspirin

RE-LY (150mg), 2009 - dabigatran 150mg vs warfarin standard dose

RE-LY (110mg), 2009 - dabigatran 110mg vs warfarin standard dose

Lip (phase 2 AZD0837), 2009 - AZD0837 vs warfarin standard dose

AMADEUS, 2008 - idraparinux vs warfarin standard dose

PETRO (150mg), 2007 - dabigatran 150mg vs warfarin standard dose

Japanese AF Trial, 2006 - aspirin vs control

ACTIVE W, 2006 - aspirin + clopidogrel vs anticoagulant

SPORTIF V, 2005 - ximelagatran vs warfarin standard dose

NASPEAF (triflusal vs coumadin standard dose)), 2004 - triflusal vs coumadin standard dose

NASPEAF (triflusal + coumadin medium dose vs coumadin standard dose), 2004 - triflusal+coumadin medium dose vs coumadin standard dose

NASPEAF (triflusal+coumadin medium dose vs triflusal), 2004 - triflusal+coumadin medium dose vs triflusal

SAFT(warfarin low dose + aspirin vs no treatment), 2003 - warfarin low dose + aspirin vs control

SPORTIF III, 2003 - ximelagatran vs warfarin standard dose

SPORTIF II (ximelagatran vs warfarin standard dose), 2002 - ximelagatran vs warfarin standard dose

PATAF (coumadin low dose vs coumadin standard dose), 1999 - coumadin low dose vs coumadin standard dose

PATAF (vs coumadin standard dose), 1999 - aspirin vs coumadin standard dose

LASAF(aspirin vs no treatment), 1999 - aspirin vs control

PATAF (vs coumadin low dose), 1999 - aspirin vs coumadin low dose

AFASAK II (aspirin vs warfarin low dose), 1998 - aspirin vs warfarin low dose

AFASAK II (warfarin low dose+aspirin vs warfarin standard dose), 1998 - warfarin + aspirin vs warfarin standard dose

PETRO (150mg) study, 2007	TRC7217
	download pdf: dabigatran 150mg | antithrombotics for atrial fibrillation

Treatments

Studied treatment	dabigatran 150 mg twice daily (alone or combined with 81- or 325-mg aspirin)
Control treatment	warfarin administered to achieve an international normalized ratio of 2 to 3 for
Remarks	factorial design: Three doses of dabigatran etexilate (50, 150, and 300 mg twice daily) were combined in a 3 3 factorial fashion with no aspirin or 81- or 325-mg aspirin once daily.

Patients

Patients	patients with AF at high risk for thromboembolic events
Baseline characteristics	age(mean) 70y  hypertension(%) 71%  diabete mellitus(%) 25%  prior TIA or stroke(%) 17.3%  heart failure(%) 29.3%  current smoker(%) 72.7%  subgroup test c

Method and design

Randomized effectives	166 / 70 (studied vs. control)
Design	Factorial plan
Blinding	double blind
Follow-up duration	12 weeks
Number of centre	53
Geographic area	Denmark, The netehrlands, Sweden, US
Primary endpoint	bleedings

Results

No results available for this trial - no clinical endpoint reported

Meta-analysis of all similar trials:

antithrombotics in atrial fibrillation for primary prevention of thromboembolic events

direct antithrombins in atrial fibrillation for all type of patients

new oral anticoagulants in atrial fibrillation for all type of patients

Reference(s)

TrialResults-center ID	TRC7217
Trials register #	NA
Study web site link	,